BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 20633967)

  • 1. Unprovoked venous thromboembolism: Short term or indefinite anticoagulation? Balancing long-term risk and benefit.
    Rodger M; Carrier M; Gandara E; Le Gal G
    Blood Rev; 2010; 24(4-5):171-8. PubMed ID: 20633967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term anticoagulation for venous thromboembolism: duration of treatment and management of warfarin therapy.
    Kearon C
    Clin Chest Med; 2010 Dec; 31(4):719-30. PubMed ID: 21047578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral anticoagulant therapy in venous thromboembolism.
    Cosmi B; Palareti G
    Semin Vasc Med; 2003 Aug; 3(3):303-14. PubMed ID: 15199464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duration of anticoagulant therapy for venous thromboembolism: balancing benefits and harms on the long term.
    de Jong PG; Coppens M; Middeldorp S
    Br J Haematol; 2012 Aug; 158(4):433-41. PubMed ID: 22734929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Optimum duration of anticoagulant treatment after an episode of venous thromboembolism].
    Couturaud F; Kearon C
    Rev Pneumol Clin; 2008 Dec; 64(6):305-15. PubMed ID: 19084210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Optimal duration of anticoagulation of venous thromboembolism].
    Savina EN; Couturaud F
    J Mal Vasc; 2011 Dec; 36 Suppl 1():S28-32. PubMed ID: 22177766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term management of patients after venous thromboembolism.
    Kearon C
    Circulation; 2004 Aug; 110(9 Suppl 1):I10-8. PubMed ID: 15339876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term anticoagulation treatment for acute venous thromboembolism in patients with and without cancer. The SWIss Venous ThromboEmbolism Registry (SWIVTER) II.
    Spirk D; Ugi J; Korte W; Husmann M; Hayoz D; Baldi T; Frauchiger B; Banyai M; Aujesky D; Baumgartner I; Kucher N
    Thromb Haemost; 2011 Jun; 105(6):962-7. PubMed ID: 21475778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended therapy for primary and secondary prevention of venous thromboembolism.
    Conway SE; Marcy TR
    J Pharm Pract; 2010 Aug; 23(4):313-23. PubMed ID: 21507831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Duration of anticoagulant therapy after initial idiopathic venous thromboembolism.
    Frazee LA; Chomo DL
    Ann Pharmacother; 2003 Oct; 37(10):1489-96. PubMed ID: 14519045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term use of different doses of low-molecular-weight heparin versus vitamin K antagonists in the treatment of venous thromboembolism.
    Romera-Villegas A; Cairols-Castellote MA; Vila-Coll R; Martí-Mestre X; Colomé E; Iguaz I
    Ann Vasc Surg; 2010 Jul; 24(5):628-39. PubMed ID: 19932949
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The optimal duration of anticoagulation in patients with venous thromboembolism: how long is long enough?
    Prandoni P; Piovella C; Spiezia L; Dalla Valle F; Pesavento R
    Panminerva Med; 2012 Mar; 54(1):39-44. PubMed ID: 22278115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major bleedings in the comparisons between low-molecular weight heparin versus oral anticoagulant therapy for venous thromboembolism.
    Ferretti G; Bria E; Giannarelli D; Carlini P; Felici A; Mandalà M; Ciccarese M; Papaldo P; Fabi A; Cognetti F
    Thromb Res; 2007; 119(4):525-9. PubMed ID: 16780933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of recurrent venous thromboembolism after a first oestrogen-associated episode. Data from the REVERSE cohort study.
    Le Gal G; Kovacs MJ; Carrier M; Do K; Kahn SR; Wells PS; Anderson DA; Chagnon I; Solymoss S; Crowther M; Righini M; Lacut K; White RH; Vickars L; Rodger M
    Thromb Haemost; 2010 Sep; 104(3):498-503. PubMed ID: 20539910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Venous thromboembolism: risk factors for recurrence.
    Zhu T; Martinez I; Emmerich J
    Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):298-310. PubMed ID: 19228602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unanswered questions in venous thromboembolism.
    Weitz JI
    Thromb Res; 2009; 123 Suppl 4():S2-S10. PubMed ID: 19303498
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duration of anticoagulant therapy for patients with venous thromboembolism.
    Garcia D
    Thromb Res; 2008; 123 Suppl 1():S62-4. PubMed ID: 18823648
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
    Huo MH; Muntz J
    Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of venous thromboembolism in cancer patients.
    Petralia GA; Kakkar AK
    Semin Thromb Hemost; 2007 Oct; 33(7):707-11. PubMed ID: 18000799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Heparin and low-molecular-weight heparin therapy for venous thromboembolism: will unfractionated heparin survive?
    Hull RD; Pineo GF
    Semin Thromb Hemost; 2004 Feb; 30 Suppl 1():11-23. PubMed ID: 15085462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.